Metformin in cancer prevention and therapy

Abstract

The prevalence of diabetes is dramatically increasing worldwide. The results of numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. The use of metformin, the most commonly prescribed drug for type 2 diabetes, was repeatedly associated with the decreased risk of the occurrence of various types of cancers, especially of pancreas and colon and hepatocellular carcinoma. This observation was also confirmed by the results of numerous meta-analyses. There are however, several unanswered questions regarding the exact mechanism of the anticancer effect of metformin as well as its activity against various types of cancer both in diabetic and nondiabetic populations. In the present work we discuss the proposed mechanism(s) of anticancer effect of metformin and preclinical and clinical data suggesting its anticancer effect in different populations.

The prevalence of diabetes is dramatically increasing worldwide reaching epidemic proportion. Landmark of diabetes, chronic hyperglycemia leads to the development and progression of life-treating complications, predominantly cardiovascular. The results of several studies indicate that people with diabetes (mainly type 2, T2DM) are also at substantially higher risk of cancer of the pancreas, liver, endometrium, breast, colon, rectum and urinary bladder compared to individuals without this chronic disease (1). However, the incidence of other types of cancer (e.g., lung, kidney, non-Hodgkin lymphomas) does not seem to be strongly associated with diabetes or the evidence is inconclusive (2). Interestingly enough, it has been suggested that diabetes is associated with a lower risk for prostate cancer (2,3). According to the American Diabetes Association and the American Cancer Society consensus report the relative risks imparted by diabetes are greatest (about two fold or higher) for cancers of the liver, pancreas, and endometrium, and lesser (about 1.2-1.5 fold) for cancers of the colon and rectum, breast, and bladder (2). Clinical observations indicate that the prevalence of diabetes in newly diagnosed cancer patients ranges from 8% to 18%, suggesting bidirectional association between these two disease (4,5). The association of diabetes and cancer was first reported as an incidental finding in 1932 (6). Nowadays, this coexistence is well recognized, however in spite of the intensive studies its mechanism still remains unclear. There is a general agreement that T2DM and cancer share several common potential risk factors (e.g., aging, sex, obesity, physical inactivity, diet, alcohol, and smoking). In T2DM, insulin resistance and hyperinsulinemia (either endogenous due to insulin resistance or induced by administration of exogenous insulin formulations) are considered to be independent risk factors for cancer development (1,2). In addition, hyperglycemia-related oxidative stress, accumulation of advances glycation end products as well as low-grade inflammation may also enhance the risk of malignant transformation (7,8). Recent publications have also suggested the link between hypoglycemic medications and cancer (8-11). The results of numerous preclinical, epidemiological and clinical studies suggested that metformin use is associated with inhibition of cancer cell growth and proliferation and reduction in all-cancer incidents in comparison with users of other hypoglycemic drugs. In the present work we discuss the proposed mechanism(s) of anticancer effect of metformin as well as preclinical and clinical data suggesting this beneficial effect.

Molecular action of metformin in cancer cell

The current proposed anticancer molecular action of metformin is mainly associated with the inhibition of the mammalian target of rapamycin complex 1 (mTORC1). The mTOR pathway plays a pivotal role in metabolism, growth and proliferation of cancer cell (12). Metformin is thought to inhibit mTORC1 pathway (Figure 1).

Figure 1.

Proposed molecular action of metformin in cancer cells. Abbreviations: Akt, protein kinase B; AMPK, AMP-activated protein kinase; Atg13, autophy-related protein 13; 4EBP1, eIF4E binding ptotein, eIF4E, eukaryotic translation initiation factor 4E; PI3K, phosphoinositide 3-kinase; p70S6K, ribosomal protein S6 kinase; Rag GTPase, Ras-related GTPase; REDD1, regulated in development and DNA damage responses 1; TSC2, tuberous sclerosis complex protein 2.

It is believed that systemic effect of metformin manifested by the reduction of circulating level of insulin and insulin-like growth factor 1 (IGF-1) might be associated with anticancer action (13). Insulin/IGF-1 is involved not only in regulation of glucose uptake but also in carcinogenesis through upregulation of insulin/IGF receptor signaling pathway (14). The excessive food consumption (insulin) leads to increased liver production of IGF-1 that binds to IGF-1 receptor and insulin receptor. Then, through insulin receptor substrate (IRS) the signal is transmitted to phosphoinositide 3-kinase (PI3K), and Akt/protein kinase B (PKB) that indirectly activates (not phosphorylates) mTORC1. Additionally, insulin receptor through growth factor receptor-bound protein 2 (GRB2) propagates signal to Ras/Raf/ERK pathway that drives cell growth. Evidences indicate that these pathways play important role in changes of cellular metabolism that are typical feature of tumor cells (15). Increased levels of circulating insulin/IGF1 and upregulation of insulin/IGF receptor signaling pathways were demonstrated to be involved in the formation of many types of cancer. Metformin was found to reduce insulin level, inhibit insulin/IGF signaling pathways, and modify cellular metabolism in normal and cancer cells (16).

Evidences suggest that the inhibition of mTOR pathway by metformin proceeds dependent and independent on AMP-activated protein kinase (AMPK) activation. AMPK phosphorylates tuberous sclerosis complex protein 2 (TSC2) that inhibits mTORC1 leading to decrease in protein synthesis and cell growth (17). Among the first studies that showed the participation of AMPK activation in antitumor action of metformin were researches performed on breast cancer cells (18,19). Dowling et al. showed that compound C, an inhibitor of AMPK, reversed inhibition of initiation of translation evoked by metformin (18). More recently, Mohammed et al. showed reduction of carcinoma spread in pancreas of transgenic mice fed with metformin (20). Additionally, pancreatic tissue of mice fed with metformin revealed a significant inhibition of mTOR, and an increase of phosphorylated AMPK and TSC2 (20). However, Gwinn el al. demonstrated that inhibition of mTOR could be independent on TSC2, since AMPK directly phosphorylates the rotor compartment of mTOR (21).

Several studies identified that liver kinase B1 (LKB1), a major upstream kinase of AMPK, may be involved in anticancer action of metfromin associated with inhibition of mTOR. In vitro and in vivo studies revealed that deletion of LKB1 function accelerated proliferation of tumor cell and sensitized them to activators of AMPK such as biguanide (22-24). Due to the fact that p53 expression and phosphorylation is regulated by AMPK and p53 is involved in cell metabolism and control of cell cycle its participation in metformin action is discussed. Growing evidences from in vivo and in vitro studies of various cancers revealed that metformin blocked cell cycle in G0/G1 phase with a significant decrease expression of G1 cyclins (including cyclin D1) without changes in p53 status (25-27). However, others researches indicated that inhibitory effect on cancer cell growth of metformin was associated with p53 activity (28-31). Taking together the results of preclinical studies are inconclusive whether antitumor action of metformin is associated with p53. Some investigators hypothesize that the dose of metformin may determine the effect of metformin. Yi et al. demonstrated on hepatoma cells that low concentration of metformin induced p53-dependent senescence, whereas higher doses induced apoptotic cell death (32).

Inhibition of mTOR by metformin independent on AMPK activation was demonstrated by Memmott et al. in mice lung cancer cells (16). Metformin evoked inhibition of mTOR pathway with accompanied decreasing activation of IGF-1/insulin receptor, Akt, extracellular signal-regulated kinase (ERK) without AMPK activation (16). Kalender et al. demonstrated in Drosophilla cells that inhibition of mTOR signaling induced by metformin occurred in the absence of AMPK. They reveal the existence of an alternative TSC1/2-mTOR AMPK-independent pathway mediated by RAG GTPase (33). Metformin was found to inhibit breast carcinoma cell growth through decreasing level of epidermal growth factor receptor 2 (HER2). This effect was mediated by inhibition of the mTOR effector, p70S6K1 (34). p70S6K is responsible for the phosphorylation of S6 ribosomal protein and thereby protein synthesis at the ribosome (35). Antiproliferative action of metformin related to enhancement of DNA-damage-inducible transcript 4 protein (DDIT4, REDD1) expression, a negative regulator of mTOR, was reported in prostate cancer cells by Ben Sahra et al. (36). This effect of metformin was also independent on AMPK activation (36).

The results of preclinical studies undoubtedly confirm the efficacy of metformin to inhibit cancer cell growth in vitro and to reduce tumor spread in animal models of various cancers. However, it should be stressed that molecular action of metformin is still investigated and seems to be affected by the type of tumor cell line.

Metformin and the risk of cancer

Metformin is the most commonly prescribed drug for T2DM. Its use in diabetes was shown to prevent macrovascular complications to the better extent than other oral hypoglycemic drugs as well as insulin (37,38). Additionally, the results of numerous epidemiologic studies repeatedly indicated that T2DM patients receiving metformin, compared to those taking other antidiabetic medications, had a decreased risk of the occurrence of various types of cancers (39). This observation was also confirmed by numerous meta-analyses that confirmed that metformin reduces cancer incidence by 30-50%.

Bowker et al. used databases from Saskatchewan Health (Canada) to examine the association between different therapeutic schedules of diabetes and cancer mortality in T2DM patients (10). It was observed that in T2DM patients using sulfonylureas (SU) or insulin the risk of cancer-related mortality was significantly increased compared to metformin users. A similar difference in cancer incidence in metformin users compared with SU was also reported by Evans et al. (40). The researchers used databases developed in Tayside (Scotland) to assess the influence of metformin therapy on the risk of cancer in patients with T2DM (40). They observed that metformin reduced the risk of cancer in patients with T2DM, both before and after adjusting for BMI. Additionally, they suggested the existence of the inverse relation between the dose of metformin and the risk of cancer.

Currie et al. performed a retrospective cohort study in 62,809 people older than 40 years, treated in U.K. by general practioners (41). Patients were on oral antidiabetic drugs and/or insulin. For the analysis the cohort was subdivided into four groups: metformin monotherapy, sulfonylurea monotherapy, combination therapy with metformin and sulfonylurea, or insulin. Insulin users were further subdivided into glargine, long-acting human insulin, biphasic analogue or human biphasic insulin. The observed risk of cancer in patients treated with basal human insulin alone vs. glargine alone was 1.24. Insulin therapy was associated with an increased risk for colorectal (HR =1.69) and pancreatic cancers (HR =4.63). However, when compared with metformin, this relation was not seen for breast and prostate cancers.

Franciosi et al. selected randomized studies comparing metformin and other hypoglycaemic agents as well as observational studies assessing the relation between exposure to metformin and cancer (42). Altogether, 12 randomized controlled trials and 41 observational studies met the inclusion criteria. They noted that in observational studies there was a significant association of exposure to metformin with the risk of cancer death, all malignancies, liver, colorectal, pancreas, stomach, and esophagus. Interestingly, such a relationship was not seen in randomized trials, what stresses the need for randomized trials to evaluate the efficacy of metformin as an anticancer agent.

Another meta-analysis of seventeen observational studies investigated the risk of all cancers and site-specific cancers in people with T2DM (43). Soranna et al. compared metformin with SU users. The meta-analysis showed that therapy with metformin use was associated with decreased risk for all cancer. Furthermore, except for colorectal cancer, metformin was not associated with any significant effect on the incidence of other cancers, for example, prostate and breast cancers.

In a large population-based study, a lower risk of cancer cancers was observed in patients treated with metformin in comparison with those received SU (44). The duration of diabetes was similar in both groups, but unfortunately the cause of death was not identified. That is why the researchers could not compare the association of the cancer-related mortality between metformin and SU users.

Chlebowski et al. assessed the association between diabetes, metformin use, and breast cancer among 68,019 postmenopausal women participating in Women’s Health Initiative clinical trials (45). Compared with women without diabetes, in diabetic woman the incidence of breast cancer was related to diabetes therapy. Diabetic women not treated with metformin had a slightly higher incidence of breast cancer. The association was observed for cancers positive for both estrogen receptor and progesterone receptor as well as those negative for HER2.

Home et al. (46) collected data for malignancies in Diabetes Outcome Progression Trial (ADOPT) and Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) studies. The results did not reveal significant differences in cancer incidence between metformin and rosiglitazone, however the incidence of cancer was slightly higher in SU group. One should remember that the number of malignancies was small in both trials.

Zhang et al. pooled the currently available data to examine the association between metformin therapy and colorectal cancer among patients with T2DM (47). More than 108,161 patients with T2DM were included into analysis, and once again they noted that metformin treatment was associated with a significantly lowest risk of colorectal cancer.

Noto et al. calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence in 21,195 diabetic patients (48). Similarly to the results of other trials they noted that the use of metformin in diabetic patients was associated with significantly lower risks of both cancer incidence and mortality.

The positive correlation between metformin use and incidence of various type cancers was not universally noted by all investigators. Mamtani et al. analysed data from 87,600 patients with T2DM (49). They assessed the incidence of bladder cancer in new users of metformin and SU and did not see any association between metformin use and this type cancer.

It is still uncertain, whether the observed increased risk of cancer mortality in diabetic patients are related to a protective effect of metformin or negative effects of other therapies including SU and insulin (40). Again, if the difference in cancer-related mortality is related to the antidiabetic drugs, it may be associated with either the slower development of the cancer or better response to anticancer therapy. Additionally, one should also remember, that there are important differences in the characteristics of patients treated with metformin compared with other antidiabetic agents. These differences may be responsible for the observed differences in cancer incidence. In the United Kingdom metformin users had a higher BMI, a younger age, a lower systolic blood pressure, a lower prevalence of cardiovascular disease, and a higher proportion of aspirin and NSAID use as compared with second-generation SU users at the beginning of therapy (50,51).

Clinical evidence with metformin in cancer prevention and treatment

Biguanides were used in oncology more than 40 years ago as “metabolic rehabilitation” in breast, colorectal, or gastric cancers patients (52). The therapy with biguanides used with caloric restriction resulted in diminished tumor development and lower incidence of metastases (53). However, until now we do not have conclusive data on the role of metformin neither in cancer prevention nor the therapy both in diabetic and non-diabetic populations.

Several studies assessed the influence of metformin on metabolic status in cancer patients with and without diabetes. It was observed in nondiabetic woman that in the early stage breast cancer metformin reduced fasting insulin by 22% and improved several metabolic parameters (54). In a randomized study in woman with breast cancer, Campagnoli et al. observed that doses of metformin used routinely in diabetes decreased testosterone and insulin levels as well as several indices of insulin resistance (55). In another study in non-diabetic women with breast cancer the therapy with metformin resulted not only in reduced number of Ki67-positive cancer cells but also in changes in gene expression of molecules involved in the mTOR and AMPK pathways (56). In a randomized study, Hosono et al. showed that compared to control group metformin in small doses (250 mg/day) reduced colorectal aberrant crypt foci (regarded as surrogate marker for colorectal cancer) by 40% in non-diabetic patients (57).

Jiralerspong et al. observed 2,529 females with breast cancer. They noted increased incidence of complete response rates in metformin group, both in patients with and without diabetes (58). However, despite the increased incidence of complete response rates, metformin did not significantly improve survival. Margel et al. assessed the relation between duration of metformin therapy after prostate cancer diagnosis and mortality in patients with diabetes (59). The data were obtained from several databases in Ontario (Canada). In the cohort consisting of 3,837 patients, they noted that the longer duration of metformin treatment after diagnosis of prostate cancer was associated with a significant decrease not only in the risk of cancer-specific but also in all-cause mortality.

Metformin was also used as adjuvant therapy in cancer patients, and most of the cancer clinical trials of metformin use the same doses typically used to treat diabetes.

Summary

Preclinical evidence suggests that metformin appears to inhibit the proliferation and growth of certain types of cancer. Results of numerous clinical studies, although inconclusive, indicate that metformin use, and possibly cumulative duration of therapy and cumulative dose, is associated not only with decreased incidence of cancer in diabetic population, but also with the better outcome in cancer patients. Considering the possible variations in response to metformin in cancer patients it seems crucial to identify target populations for its use. However, factors contributing to better outcome in metformin users, such as genetic polymorphisms, are still to be elucidated (60). The definite data on the efficacy of metformin as neoadjuvant therapy in cancer patients is lacking. There are numerous trials underway in prostate cancer patients receiving androgen deprivation therapy as well as in patients with small benign thyroid nodules and insulin resistance (61,62). Altogether, there are currently more than 100 ongoing or upcoming clinical studies assessing the role of metformin in the therapy cancer (Tables 1 and 2). The vast majority of current trials assess the usefulness of metformin in cancer treatment, while several trials evaluate metformin in cancer prevention. Their results will permit to assess the place of metformin in cancer prevention and therapy, and define the target populations in the nearest future.

Table 1. The ongoing and upcoming clinical trials with metformin in cancer prevention (63).

Trial	ClinicalTrials.gov identifier	Phase	Measured endpoints
Exercise and metformin in colorectal cancer survivors	NCT01340300	II	Insulin levels and other biomarkers
An endometrial cancer chemoprevention study of metformin	NCT01697566	III	Biomarkers in the endometrium and insulin levels
Metformin as a chemoprevention agent in non-small cell lung cancer	NCT01717482	II	Progression of potentially precancerous bronchial lesions (secondary endpoint) in patients who have undergone surgery for lung cancer
Metformin hydrochloride as chemoprevention in patients with barrett esophagus	NCT01447927	II	Changes in the levels of the signaling pathway protein pS6K1, thought to play important role in progression to esophageal cancer

Table 2. The ongoing and upcoming clinical trials with metformin in cancer therapy (63).

Study	ClinicalTrials.gov identifier	Conditions	Interventions
Exercise and metformin in colorectal and breast cancer survivors	NCT01340300	Colorectal cancer; breast cancer	Behavioral: exercise training; drug: exercise training plus metformin; drug: metformin; other: educational information
Effect of metformin on breast cancer metabolism	NCT01266486	Breast cancer	Drug: metformin
Temsirolimus in combination with metformin in patients with advanced cancers	NCT01529593	Advanced cancers	Drug: temsirolimus; drug: metformin
Clinical and biologic effects of metformin in early stage breast cancer	NCT00897884	Breast cancer	Drug: metformin
Metformin and endometrial cancer	NCT01205672	Endometrial cancer	Drug: metformin
A trial of standard chemotherapy with metformin (vs. placebo) in women with metastatic breast cancer	NCT01310231	Metastatic breast cancer	Drug: metformin; drug: placebo
Metformin plus modified FOLFOX 6 in metastatic pancreatic cancer	NCT01666730	Acinar cell adenocarcinoma of the pancreas; duct cell adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage IV pancreatic cancer	Drug: metformin hydrochloride; drug: oxaliplatin; drug: leucovorin calcium; drug: fluorouracil; other: laboratory biomarker analysis
Phase II study of metformin for reduction of obesity-associated breast cancer risk	NCT02028221	Breast cancer prevention	Drug: metformin; drug: placebo
Metformin hydrochloride as first-line therapy in treating patients with locally advanced or metastatic prostate cancer	NCT01243385	Prostate cancer	Drug: metformin hydrochloride
Pre-surgical trial of the combination of metformin and atorvastatin in newly diagnosed operable breast cancer	NCT01980823	Breast cancer; breast tumors; cancer of breast	Drug: metformin, atorvastatin combination
Impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) and related pharmacodynamic markers	NCT01440127	Colon cancer	Drug: metformin
Metformin hydrochloride vs. placebo in overweight or obese patients at elevated risk for breast cancer	NCT01793948	Breast cancer; obesity	Drug: metformin hydrochloride; other: placebo; other: laboratory biomarker analysis
Evaluation of metformin, targeting cancer stem cells for prevention of relapse in GYN patients	NCT01579812	Ovarian, fallopian tube, and primary peritoneal cancer	Drug: metformin
Effect of metformin on biomarkers of colorectal tumor cell growth	NCT01632020	Colorectal neoplasms	Drug: placebo; drug: metformin
Metformin in children with relapsed or refractory solid tumors	NCT01528046	Solid tumors; primary brain tumors	Drug: vincristine sulfate; drug: irinotecan; drug: temozolomide; drug: metformin
Metformin hydrochloride in treating patients with prostate cancer undergoing surgery	NCT01433913	Adenocarcinoma of the prostate; recurrent prostate cancer; stage I prostate cancer; stage IIA prostate cancer; stage IIB prostate cancer	Drug: metformin hydrochloride; other: placebo; other: laboratory biomarker analysis
Metformin hydrochloride in treating women with stage I or stage II breast cancer that can be removed by surgery	NCT00984490	Breast cancer	Drug: metformin hydrochloride; other: laboratory biomarker analysis
Castration compared to castration plus metformin as first line treatment for patients with advanced prostate cancer	NCT01620593	Prostate cancer	Drug: placebo and castration; drug: metformin and castration
Metformin with the levonorgestrel-releasing intrauterine device for the treatment of complex atypical hyperplasia (CAH) and endometrial cancer (EC) in non-surgical patients	NCT02035787	Complex atypical hyperplasia; endometrial cancer	Drug: metformin
Metformin hydrochloride, carboplatin, and paclitaxel in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer	NCT02050009	Ovarian papillary serous carcinoma; ovarian serous cystadenocarcinoma; recurrent fallopian tube cancer; recurrent ovarian epithelial cancer; recurrent ovarian germ cell tumor; recurrent primary peritoneal cavity cancer	Drug: metformin hydrochloride; drug: carboplatin; drug: paclitaxel; other: laboratory biomarker analysis
The metformin active surveillance trial (MAST) study	NCT01864096	Prostate cancer	Drug: metformin; drug: placebo
Metformin plus irinotecan for refractory colorectal cancer	NCT01930864	Colorectal neoplasms; adenocarcinoma	Drug: metformin; drug: irinotecan
Metformin-docetaxel association in metastatic hormone-refractory prostate cancer	NCT01796028	Prostatic neoplasms	Drug: metformin; drug: placebo; drug: taxotere®
Metformin combined with gemcitabine as adjuvant therapy for pancreatic cancer after curative resection	NCT02005419	Stage IA pancreatic adenocarcinoma; stage IB pancreatic adenocarcinoma; stage IIA pancreatic adenocarcinoma; stage IIB pancreatic adenocarcinoma	Drug: gemcitabine; drug: metformin; drug: placebo
An endometrial cancer chemoprevention study of metformin	NCT01697566	Gynecology	Drug: metformin; other: placebo; procedure: endometrial biopsy; behavioral: lifestyle intervention; behavioral: questionnaires
Metformin and 5-fluorouracil for refractory colorectal cancer.	NCT01941953	Metastatic colorectal cancer	Drug: metformin and fluorouracil
Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma	NCT00659568	Breast cancer; endometrial cancer; kidney cancer; lung cancer; lymphoma; unspecified adult solid tumor, protocol specific	Drug: metformin hydrochloride; drug: temsirolimus
Metformin in castration-resistant prostate cancer	NCT01215032	Prostate cancer	Drug: metformin
Metformin and carbohydrate restriction with platinum based chemotherapy in stage IV NS-NSCLC	NCT02019979	Non-small cell lung cancer stage IIIB; non-small cell lung cancer metastatic; non squamous non-small cell neoplasm of lung	Drug: metformin; behavioral: carbohydrate restricted diet
Study of erlotinib and metformin in triple negative breast cancer	NCT01650506	Breast cancer	Drug: metformin; drug: erlotinib
a study with or without metformin to determine if metformin can prevent weight gain and other problems (i.e., diabetes, increased cholesterol, etc.) that can arise from the use of hormonal therapy in combination with radiation therapy when treating aggressive localized prostate cancer	NCT01996696	Prostatic neoplasm	Drug: metformin; drug: placebo
Studying changes in breast density in patients with early-stage breast cancer treated with metformin hydrochloride or placebo on CAN-NCIC-MA.32	NCT01666171	Breast cancer	Drug: metformin hydrochloride; other: clinical observation; other: diagnostic laboratory biomarker analysis; other: imaging biomarker analysis; other: medical chart review; Procedure: digital mammography
Lapatinib with sirolimus or metformin	NCT01087983	Advanced cancers	Drug: lapatinib; drug: sirolimus; drug: metformin
RAD/letrozole/metformin	NCT01797523	Endometrial cancer	Drug: metformin; drug: letrozole; drug: everolimus
Study of biomarkers associated with fatigue in patients with early-stage breast cancer treated with metformin or placebo on NCIC-CTG-MA.32	NCT01286233	Breast cancer; depression; fatigue; sleep disorders	Drug: metformin; drug: placebo
Effect of metformin on decrement in levothyroxin dose required for thyroid stimulating hormone (TSH) suppression in patients with differentiated thyroid cancer	NCT01341886	Malignant neoplasm of thyroid stage I; malignant neoplasm of thyroid stage II	Drug: metformin
Phase I factorial trial of temozolomide, memantine, mefloquine, and metformin for post-radiation therapy (RT) glioblastoma multiforme (GBM)	NCT01430351	Brain cancer	Drug: temozolomide; drug: memantine; drug: mefloquine; drug: metformin
Metformin in stage IV lung adenocarcinoma	NCT01997775	Non-small cell lung cancer	Drug: metformin
A randomized, placebo-controlled, double-blind phase II study evaluating if glucophage can avoid liver injury due to chemotherapy associated steatosis	NCT01523639	Colorectal cancer; steatohepatitis	Drug: metformin/placebo

NSCLC, non-small cell lung cancer.